Glenmark launches Winlevi across key European markets

First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe

Cipla elevates Manoj Dimri as Group Business Head

Pharma industry veteran brings extensive experience in commercial strategy, business growth, and market leadership to his expanded role at Cipla

Glenmark launches generic Lacosamide Injection USP in US Market

Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually

Glenmark posts strong FY26 results with 27.5% revenue jump

Ashish Mukkirwar appointed CFO of Jubilant Pharmova

The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives

Akumentis Healthcare appoints Dharnendra Doshi as Senior Vice President

Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels

Drug Safety Symposium 2026 to focus on real-world impact of pharmacovigilance

The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations

6th Drug Safety Symposium 2026 to convene over 100 pharmacovigilance leaders

Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption

Glenmark gets USFDA approval for generic Endometrin vaginal inserts

Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety